HL156A is a derivative of
metformin and a potent
OXPHOS inhibitor and
AMPK activating biguanide.
Certain types of cancer cells requires OXPHOS to survive. By targeting it, HL156A might help in improving anticancer therapy.
It is more potent than
AICAR or metformin at activating AMPK.
It is synthesized by Hanall Biopharma.
Medical uses
It is in
phase 1 trial
The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases ...
in patients with advanced solid tumor and
lymphoma.
Pharmacology
Apart from AMPK activation, it also inhibits expression and activation of
IGF-1
Insulin-like growth factor 1 (IGF-1), also called somatomedin C, is a hormone similar in molecular structure to insulin which plays an important role in childhood growth, and has anabolic effects in adults.
IGF-1 is a protein that in humans is ...
,
AKT,
mTOR, and
ERK.
Research
It is researched in multiple conditions like liver and renal
fibrosis,
and drug resistance in cancer.
A drug HL176OUT04 with similar pharmacology has been also developed.
See also
*
Phenformin
References
{{Reflist
Pyrrolidines
Guanidines
Trifluoromethyl ethers
Phenols